echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The State Food and Drug Administration approved the import registration of Monoravir capsules, Merck's new coronavirus treatment drug

    The State Food and Drug Administration approved the import registration of Monoravir capsules, Merck's new coronavirus treatment drug

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the official website of the State Food and Drug Administration, on December 29, in accordance with the relevant provisions of the Drug Administration Law, the State Food and Drug Administration conducted emergency review and approval in accordance with the special approval procedures for drugs, and conditionally approved the import registration
    of Merck's new coronavirus treatment drug monogravir capsules (trade name: Lizhuorui/LAGEVRIO).

    This product is an oral small molecule new coronavirus treatment drug, which is used to treat adult patients with mild to moderate novel coronavirus infection (COVID-19) with risk factors for progression to severe disease, such as patients with advanced age, obesity or overweight, chronic kidney disease, diabetes, severe cardiovascular disease, chronic obstructive pulmonary disease, active cancer and other high-risk factors for severe disease
    .
    Patients should take the drug strictly according to the instructions under the
    guidance of a physician.
    (Zhongxin Finance)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.